Effects of supplementation with polyphenol resveratrol in patients with diabetes mellitus type 2: a systematic review

Authors

DOI:

https://doi.org/10.33448/rsd-v9i10.8659

Keywords:

Resveratrol; Diabetes mellitus; Glucose; Oxidative stress.

Abstract

The present study aimed to review the effects of resveratrol supplementation in patients diagnosed with DM2. This is a systematic review, carried out using the electronic databases PubMed, Lilacs and Medline, published in English, from 2011 to 2019, with the descriptors "Resveratrol" and "Diabetes Mellitus". The inclusion criteria used were: randomized clinical trials conducted with individuals with type 2 DM. Studies with animals, pregnant women, lactating women, and individuals under the age of 18 years were excluded. It was observed that the effects of resveratrol supplementation more prevalent in these patients were related to improved insulin sensitivity, glycemic control and a possible reduction in oxidative stress. There are still controversies in the literature regarding its real effectiveness in diabetic patients. However, the use of resveratrol as an adjunct to hypoglycemic therapy is not ruled out.

References

American Diabetes Association-ADA. (2019). Classification and Diagnosis of diabetes mellitus. Diabetes Care. 42 (Supl1), 513-528. https://www.diabetes.org.br /profissionais/images/pdf/Diretriz-2019-ADA.pdf

Avogaro, A., Kreutzenberg, S. V., & Fadini, G. (2008). Endothelial dysfunction: Causes and consequences in patients with diabetes mellitus. Diabetes Research and Clinical Practice, 82:S94–S101. https://doi.org/10.1016/j.diabres.2008.09.021

Bashmakov, Y. K., Assaad-Khalil, S., & Petyaev, I. M. (2011). Resveratrol may be beneficial in treatment of diabetic foot syndrome. Medical Hypotheses, 77(3), 364–367. https://doi.org/10.1016/j.mehy.2011.05.016

Bashmakov, Y. K., Assaad-khalil, S. H., Abou seif, M., Udumyan, R., Megallaa, M., Rohoma, K. H., et al. (2014). Resveratrol Promotes Foot Ulcer Size Reduction in Type 2 Diabetes Patients. ISRN Endocrinology, 2014:1–8. https://doi.org/10.1155/2014/816307

Bhatt, J. K., Thomas, S., & Nanjan, M. J. (2012). Resveratrol supplementation improves glycemic control in type2 diabetes mellitus. Nutrition Research. 32(7), 537–541. https://doi.org/10.1016/j.nutres.2012.06.003

Bo, S., Ponzo, V., Ciccone, G., Evangelhista, A., Saba, F., Goitre, I., et al. (2016). Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial. Pharmacological Research, 111:896–905. https://doi.org/10.1016/j.phrs.2016.08.010

Bo, S., Ponzo, V., Evangelista, A., Ciccone, G., Goitre, I., Saba, F., et al. (2017). Effects of 6 months of resveratrol versus placebo on pentraxin 3 in patients with type 2 diabetes mellitus: a double-blind randomized controlled trial. Acta Diabetologica. 54(5),499–507. https://doi.org/10.1007/s00592-017-0977-y

Bode, L.M., Bunzel, D., Huch, M., Cho, G.S., Ruhland, D., Bunzel, M., et al. (2013). In vivo and in vitro metabolism of trans-resveratrol by human gut microbiota. Am J Clin Nutr, 97(2), 295–309. https://doi.org/10.3945/ajcn.112.049379

Brasnyo, P., Molnar, G.A., Mohás, M., Marko, L., Laczy, B., Cseh, J., et al. (2011). Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr. 106(3), 383-389. https://doi.org/10.1017/S0007114511000316

Chen, W.P., Chi, T.C., Chuang, L.M., & Su, M. (2007). Resveratrol enhances insulin secretion by blocking KATP and KV channels of beta cells. Eur J Pharmacol, 568(1-3), 269–77. https://doi.org/10.1016/j.ejphar.2007.04.062

Christenson, J., Whitby, S. J., Mellor, D., Thomas, J., McKune, A., Roach, P. D, et al. (2016). The efects of resveratrol supplementation in overweight and obese humans: a systematic review of randomized trials. Metab Syndr Relat Disord, 14(7), 323–333. https://doi.org/10.1089/met.2016.0035

Dalle-donne, I., Rossi, R., Giustarini, D., Milzani, A., & Colombo, R. (2003). Protein carbonyl groups as biomarkers of oxidative stress. Rev.Clin Chim Acta. 329(1-2), 23–38. https://doi.org/10.1016/S0009-8981(03)00003-2.

Daniel. R., Gokulanathan, S., Shanmugasundaram, N., Lakshmigandhan, M., & Kavin, T. (2012). Diabetes and periodontal disease. J Pharm Bioallied Sci, 4(2), 280–282. https://doi.org/10.4103/0975-7406.100251

Do, G. M., Jung, U. J., Park, H. J., Kwon, E. Y., Jeon, S. M, McGregor, R. A., et al. (2012). Resveratrol ameliorates diabetes-related metabolic changes via activation of AMPactivated protein kinase and its downstream targets in db/db Mice. Molecular Nutrition & Food Research.56(8),1282–1291. https://doi.org/10.1002/mnfr.201200067

Elgebaly, A., Radwan, I. A., Aboelnas, M. M., Ibrahim, H. H., Eltoomy, M. F. M, Atta, A. A, et al. (2017). Resveratrol supplementation in patients with non-alcoholic fatty liver disease: systematic review and meta-analysis. J Gastrointest Liver Dis, 26(1),59–67. https://doi.org/10.15403/jgld.2014.1121.261.ely.

Evans, J. L., Maddux, Ba., & Goldfine, I. D. (2005). The molecular basis for oxidative stress induced insulin resistance. Antioxid Redox Signal, 7(7), 1040–1052. https://doi.org/10.1089/ars.2005.7.1040

Faghihzadeh, F., Adibi, P., Rafei, R., & Hekmatdoost, A. (2014). Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res, 34(10):837–843. https://doi.org/10.1016/j.nutres.2014.09.005

Ghanim, H., Sai, C. L., Abuaysheh, S., Korzeniewski, K., Patnaik, P., Marumganti, A., et al. (2010). An Antiinflammatory and Reactive Oxygen Species Suppressive Effects of an Extract ofPolygonum CuspidatumContaining Resveratrol. The Journal of Clinical Endocrinology & Metabolism. 95(9),1–8. https://doi.org/10.1210/jc.2010-482

Glodzik, L., Randall, C., Rusinek, H., & de Leon, M. J. (2013). Cerebrovascular reactivity to carbon dioxide in Alzheimer’s disease. A review. Journal of Alzheimer's disease. 35(3),427-40. https://doi.org/10.3233/JAD-122011

Gregg, E. W., Sattar N., & Ali, M. K. (2016). The changing face of diabetes complications. Lancet Diabetes Endocrinol. 4(6), 537-47. https://doi.org/10.1016/S2213-8587(16)30010-9

Groote, D., Van belleghem, K., Deviere, J., Van Brussel, W., Mukaneza, A., Amininejad, L., et al. (2012). Efect of the intake of resveratrol, resveratrol phosphate, and catechin-rich grape seed extract on markers of oxidative stress and gene expression in adult obese subjects. Rev. Ann Nutr Metab. 61(1),15–24. https://doi.org/10.1159/000338634

Grover, H. S., & Luthra, S. (2013). Molecular mechanisms involved in the bidirectional relationship between diabetes mellitus and periodontal disease. J Indian Soc Periodontol, 17(3), 292–301. https://doi.org/10.4103/0972-124X.115642

Hahn, G. F., Oliveira, J. R., & Bock, P. M. (2017). The role of factor 2 erythroid nuclear factor 2 (Nrf2) in diabetes mellitus. Clin Biomed Res. 37(3), 203-213.

Hu, P., Zhao, L., & Chen, J. (2014). Physiologically achievable doses of resveratrol enhance 3T3-L1 adipocyte diferentiation. Eur J Nutr, 54(4), 569–579. https://doi.org/10.1007/s00394-014-0738-4

Imamura, H., Yamaguchi, T., Nagayama, D., Saik, A., Shirai, K., & Tatsuno, I. (2017). Resveratrol ameliorates arterial stifness assessed by cardio-ankle vascular index in patients with type 2 diabetes mellitus. Int Heart J. 58(4):577–583. https://doi.org/10.1536/ihj.16-373

International Diabetes Federation. IDF Atlas. 8. ed. Bruxelas: International Diabetes Federation; 2017. Recuperado de https://www.diabetesatlas.org/em /resources/?gclid=CjwKCAjw19z6BRAYEiwAmo64LS_2q5VvWM1E-J

Javid, Z. A., Hormoznejad, R., Yousefimanesh, H., Zakerkish, M., Haghighi‐zadeh, M. H., Dehghan, P., et al. (2016). The Impact of Resveratrol Supplementation on Blood Glucose, Insulin, Insulin Resistance, Triglyceride, and Periodontal Markers in Type 2 Diabetic Patients with Chronic Periodontitis. Phytotherapy Research, 31(1),108–114. https://doi.org/10.1002/ptr.5737

Jiang, W.J. (2008). Sirtuins: novel targets for metabolic disease in drug development. Biochem Biophys Res Commun, 373(3), 341–344. https://doi.org/10.1016/j.bbrc.2008.06.048

Juhasz, B., Varga, B., Gesztelyi, K. A., Zsuga, J., & Tosaki, A. (2010). Resveratrol: a multifunctional cytoprotective molecule. Current Pharmaceutical Biotechnology. 11(8), 810–818. https://doi.org 10.2174/138920110793262079

Kennedy, D. O., Wightman, E. L., Reay, J. L., Lietz, G., Okello, E. J., Wilde. A., et al. (2010). Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. Am J Clin Nutr, 91(6),1590-7. https://doi.org/10.3233/JAD-122011

Kim, S., Jin, Y., Choi, Y., & Park, T. (2011). Resveratrol exerts anti-obesity efects via mechanisms involving down-regulation of adipogenic and infammatory processes in mice. Biochem Pharmacol, 81(11),1343–135. https://doi.org/10.1016/j.bcp.2011.03.012

Lagouge, M., Argmann, C., Gerhart-hines, Z., Meziane, H., Lerin, C., Daussin, F., et al. (2006). Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell, 127(6):1109–22. https://doi.org/10.1016/j.cell.2006.11.013

Lasa, A., Churruca, I., Eseberri, I., Andres-Lacueva, C., & Portillo, M. P. (2012) Delipidating efect of resveratrol metabolites in 3T3-L1 adipocytes. Mol Nutr Food Res, 56(10):1559–68. https://doi.org/10.1002/mnfr.201100772

Lee, H., & Ko, G. (2014). Effect of metformin on metabolic improvement and gut microbiota. Appl Environ Microbiol, 80(19), 5935–43. https://doi.org/10.1128/AEM.01357-14

Lontchi-yimagou, E., Sobngwi, E., Matsha, T. E., & Kengne, A. P. (2013) Diabetes mellitus and inflammation. Curr Diabetes Rep. 13:435–444. https://doi.org/10.1007/s11892-013-0375-y

Louis, X. L., Thandapilly, S. J., Mohankumar, S. K., Yu, L.,Taylor, C. G., Zahradka, P., et al. (2012). Treatment with low- dose resveratrol reverses cardiac impairment in obese prone but not in obese resistant rats. Journal of Nutritional Biochemistry. 23(9), 1163–9. https://doi.org/10.1016/j.jnutbio.2011.06.010

Maratos-flier, E. (2013) Metabolic disease puts up a fight: microbes, metabolism and medications. Nature Medicine, 19:1218–19. https://doi.org/10.1038/nm.3373

Méndez-del villar, M., González-ortiz, M., Martínez-abundis, E., Karina, G., Perez, R., & Valdez, R .L. (2014). Efect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord, 12(10):497–501. https://doi.org/10.1089/met.2014.0082

Movahed, A., Nabipour, I., Lieben, L. X., Thandapilly, S. J., Yu, L., Kalantarhormozi, M., et al. (2013). Antihyperglycemic effects of short termresveratrol supplementation in type 2 diabetic patients. Evid Based Complement Alternat Med, 2013,1-11. https://doi.org/10.1155/2013/851267

Pereira, A. S., Shitsuka, D. M., Parreira, F. J., & Shitsuka, R. (2018). Metodologia da pesquisa científica. [e-book]. Santa Maria. Ed. UAB/NTE/UFSM. Recuperado de https://repositorio.ufsm.br/bitstream/handle/1/15824/Lic_Computacao_MetodologiaPesquisa-Cientifica.pdf?sequence=1.

Rivera, L., Moro, N. R., Zarzuelo, A., & Galisteo, M. (2009). Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol, 77(6),1053–63. https://doi.org/10.1016/j.bcp.2008.11.027

Schmatz, R., Perreira, L.B., Stefanello, N., Mazzanti, C., Spanevello, R., Gutierres, J., et al. (2012). Efects of resveratrol on biomarkers of oxidative stress and on the activity of delta aminolevulinic acid dehydratase in liver and kidney of streptozotocin-induced diabetic rats. Rev. Biochimie. 94(2), 374–383. https://doi.org/10.1016/j.biochi.2011.08.005

Seyyedebrahimi, S., Khodabandehloo, H., Nasliesfahani, E., & Meshkani, R. The effects of resveratrol on markers of oxidative stress in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. (2018). Rev.Acta Diabetol. 55(4),341-353. https://doi.org/10.1007/s00592-017-1098-3

Sharma, S., Misra, C. S., Arumugam, S., Roy, S., Shah, V., Davis, J. A, et al. (2011). Antidiabetic activity of resveratrol, a known SIRT1 activator in a genetic model for type-2 diabetes. Phytotherapy Research. 25(1),67–73. https://doi.org/10.1002/ptr.3221

Souf, F. G., Mohammad-nejad, D., & Ahmadieh H. (2012). Resveratrol improves diabetic retinopathy possibly through oxidative stress-nuclear fator-κB apoptosis pathway. Rev. Pharmacol. 64(6), 1505–14. https://doi.org/10.1016/S1734-1140(12)70948-9

Stanko, P., & Izakovicova Holla, L. (2014). Bidirectional association between diabetes mellitus and inflammatory periodontal disease. A review. Biomedical Papers of the Medical Faculty of the University Palacky Olomouc Czech Repub, 158(1), 35–38. https://doi.org/10.5507/bp.2014.005

Tamaki, N., Campos, R. C. O., Inagaki, Y., Fukui, M., Nagata, T., & Ito, H. O. (2014). Resveratrol improves oxidative stress and prevents the progression of periodontitis via the activation of the Sirt1/AMPK and the Nrf2/antioxidant defense pathways in a rat periodontitis model. Free Radic Biol Med, 75,222–229. https://doi.org/10.1016/j.freeradbiomed.2014.07.034

Thadapilly, S. J., Wojciechowski, P., Behbahani, J., Louis, X. L., Yu, L., Juric, D., et al. (2010). Resveratrol prevents the development of pathological cardiac hypertrophy and cantractile dysfunction in the SHR without lowering blood pressure. American Journal of Hypertension. 23(2), 192–196. https://doi.org/10.1038/ajh.2009.228

Thandapilly, S. J., Louis, X. L., Yang, T., Stringer, D. M., Yu, L., Zhang, S., et al. (2011). Resveratrol prevents norepinephrine induced hypertrophy in adult rat cardiomyocytes, by activating NO-AMPK pathway. European Journal of Pharmacology. 668(1-2), 217–224.

Thirunavukkarasu, M., Penumathsa, S. V., Koneru, S., Juhasz, B., Zhan, L., Otani H, et al. (2007). Resveratrol alleviates cardiac dysfunction in streptozotocininduced diabetes: role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic Biol Med, 43(5),720–729. https://doi.org/10.1016/j.freeradbiomed.2007.05.004

Timmers, S., De ligt, M., Phielix, E., Weijer, T. V., Hansen, J., Kornips, E M., et al. (2016). Resveratrol as Add-on Therapy in Subjects With Well-Controlled Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care, 39(12),2211–17. https://doi.org/10.2337/dc16-0499

Timmers, S., Hesselink, M. K., & Schrauwen, P. (2013). Therapeutic potential of resveratrol in obesity and type 2 diabetes: new avenues for health benefits? Ann N Y Acad Sci, 1290(1),83–89. https://doi.org/10.1111/nyas.12185

Tomé-carneiro, J., Larrosa, M., González-sarrías, A., Barberan, A. T., Garcia, T., & Juan, C. (2013). Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr Pharm Des, 19(34),6064–93. https://doi.org/10.2174/13816128113199990407

Wang, S., Liang, X., Yang, Q., Fu, X., Rogers, C. J., Zhu, M., et al. (2015) Resveratrol induces brownlike adipocyte formation in white fat through activation of AMP-activated protein kinase (AMPK) α1. Int J Obes, 39(6), 967–976. https://doi.org/10.1038/ijo.2015.23

Witte, A. V., Kerti, L., Margulies, D. S., & Floel, A. (2014). Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. The Journal of Neuroscience. 34(23),7862-70. https://doi.org/10.1523/JNEUROSCI.0385-14.2014

Yang, J. Y., Della-fera, M. A., Rayalam, S., Ambati, S., Hartzell, D. L., Park, H. J, et al. (2008). Enhanced inhibition of adipogenesis and induction of apoptosis in 3T3-L1 adipocytes with combinations of resveratrol and quercetin. Life Sci, 82(20),1032–1039. https://doi.org/10.1016/j.lfs.2008.03.003

Yu, W., Fu, Y., & Wang, W. (2012). Cellular and molecular effects of resveratrol in health and disease. Journal of Cellular Biochemistry. 113(3), 752–759. https://doi.org/10.1002/jcb.23431.

Downloads

Published

30/09/2020

How to Cite

LIMA, V. S. de; BEZERRA, A. N.; ALBUQUERQUE, N. V.; PEREIRA , C. P.; ALENCAR, C. M. da C.; LIMA, A. T. A.; FERREIRA, K. C. de A. Effects of supplementation with polyphenol resveratrol in patients with diabetes mellitus type 2: a systematic review . Research, Society and Development, [S. l.], v. 9, n. 10, p. e3639108659, 2020. DOI: 10.33448/rsd-v9i10.8659. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/8659. Acesso em: 26 apr. 2024.

Issue

Vol. 9 No. 10

Section

Health Sciences

License

Copyright (c) 2020 Valéria Silva de Lima; Alane Nogueira Bezerra; Natasha Vasconcelos Albuquerque; Camila Pinheiro Pereira ; Camila Moreira da Costa Alencar; Ana Thaís Alves Lima; Kelly Christine de Assis Ferreira

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.